

FDA-approved Therapeutics and Diagnostics from Which Dana-Farber Receives Royalty Income

DRUGS:

Commercial Name	Product Type	Type	Company	Year Approved
Uplizna (Inebilizumab-cdon)	Anti-CD19 Ab	Biologic	Horizon Therapeutics	2020
Rydapt (Midostaurin)	FLT3 inhibitor	Drug	Novartis	2017
Imfinzi (Durvalumab)	Anti-PD-L1 Ab	Biologic	AstraZeneca	2017
Bavencio (Avelumab)	Anti-PD-L1 Ab	Biologic	EMD SERONO INC	2017
Tecentriq (Atezolizumab)	Anti-PD-L1 Ab	Biologic	Genentech / Roche / Chugai	2016
Keytruda (Pembrolizumab)	Anti-PD-1 Ab	Biologic	Merck	2014
Opdivo (Nivolumab)	Anti-PD-1 Ab	Biologic	Bristol-Myers Squibb	2014

DIAGNOSTICS:

Commercial Name	Product Type	DFCI Involvement	Company	Year Approved
myChoice HRD CDx	Cancer-related germline mutation detection system	Methods of Use	Myriad Genetic Laboratories	2019
Ventana pd-I1(sp142) CDX Assay20	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Ventana / Roche	2016
PD-L1 IHC 22C3 PharmDx	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Dako	2015
PD-L1 IHC 28-8 PharmDx	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Dako	2015
Therascreen EGFT RGQ PCR Kit	EGFR Mutation Diagnostic	Methods of Use	QIAGEN	2013
Cobas EGFR mutation test	EGFR Mutation Diagnostic	Methods of Use	Roche	2013
CA 15-3 Antibody RIA	Anti-CA 15-3 Diagnostic	Composition of Matter	CENTOCOR / Fujirebio	1997
CA 125 Antibody RIA	Anti-CA 125 Diagnostic	Composition of Matter	CENTOCOR / Fujirebio	1987